Medications not yet evaluated by P&T are considered NON-FORMULARY . . . . . Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step! . . . . . Please be sure to document all clinical activities daily.
Search results for:

Basaglar KwikPen

insulin glargine
Drug Name Form Strength Formulary Unrestricted Formulary Restricted Non-Formulary Interchange
Basaglar KwikPen SOLUTION, SUBCUTANEOUS 100 units/mL    
Lantus SOLUTION, SUBCUTANEOUS 100 units/mL      
Rezvoglar SOLUTION, SUBCUTANEOUS 100 units/mL      
Semglee SOLUTION, SUBCUTANEOUS 100 units/mL    
Toujeo SoloStar SOLUTION, SUBCUTANEOUS 300 units/mL    

VIEW MORE Insulins
CLASS
682008

Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

NOTES

insulin glargine (Toujeo SoloStar)

  • 300 units/mL

insulin glargine

  • 100 units/mL

Interchanged on a 1 unit : 1 unit ratio with same dosing frequency.

insulin glargine (Basaglar Kwikpen)

  • 100 units/mL

insulin glargine

  • 100 units/mL

Interchanged on a 1 unit : 1 unit ratio with same dosing frequency.

Approved to round DOWN to nearest whole unit if calculations result in dose in fractions.

 


Standard administration times:

once daily (except qAM) = 2100

once daily in the morning = 0900

twice daily = 0900 and 2100

now = now

 


Patients with orders for the hospital’s adult sliding scale insulin order set have orders to implement the hospital’s hypoglycemia orders. However, some patients have orders for scheduled or PRN insulin without use of the sliding scale insulin order set. These patients may not have PRN orders for treatment of hypoglycemia.

To improve safety with insulin use, the following policy has been approved by the P&T Committee:

  1. Allow pharmacists to automatically implement the ADULT Hypoglycemia Orders, if not previously ordered, for adult patients receiving the following:
    1. Scheduled insulin
    2. PRN insulin
  2. The pharmacist would enter the ADULT Hypoglycemia Orders into iCare, using the Per Protocol order mode, under the name of the provider who ordered the insulin.

 


Semglee and Rezvoglar has been classified as therapeutically equivalent to Lantus for adult and pediatric patients. The most cost-effective insulin glargine product will be used in a specific patient, setting, or time period. 

 


 Reviewed: 28 July 2015 (Toujeo), and 19 Jan 2017 (Basaglar pediatrics), and 24 Jan 2017 (Basaglar), and February 2021, and June 2022 (Rezvoglar)


Last updated: Jul. 27, 2022







This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.